Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
  • Patent number: 11225516
    Abstract: A method of operating a chromatography column is described. This method involves collecting column outlet signal and accumulated flow parameters at two or more intervals of at least one mobile phase transition front during operation of the chromatography column comprising column packing. A model gamma cumulative distribution curve is calculated based on the collected column outlet signal and accumulated flow parameters for the at least one mobile phase transition front. A height equivalent theoretical plate (HETP) value is calculated for the at least one mobile phase transition front using parameters of the model gamma cumulative distribution curve and the quality of the chromatography column packing is assessed based on the calculated HETP value.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: January 18, 2022
    Inventor: Paul Randolph
  • Patent number: 10509037
    Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 17, 2019
    Assignee: Eisai, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 9487583
    Abstract: [Problem] To provide a method that efficiently produces antigen-specific monoclonal antibodies from a wide range of animal species, and to provide a new antigen-specific monoclonal antibody using this technique. [Solution] A nonhuman animal is immunized with a target antigen, lymph fluid or the like is collected from the immunized nonhuman animal, or lymph fluid or the like is collected from a human having antibodies to the target antigen, the collected lymph fluid or the like is combined with (1) a labeled target antigen and (2) a marker that can selectively binds to plasma cells and/or plasmablasts, and cells that have bound to (1) the labeled target antigen and (2) the marker are then selected.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: November 8, 2016
    Inventors: Nobuyuki Kurosawa, Masaharu Isobe
  • Patent number: 9470696
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-4 Protein (HER4) protein are provided that are particularly advantageous for quantifying the HER4 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 18, 2016
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 9075061
    Abstract: The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: July 7, 2015
    Assignee: PamGene B.V.
    Inventors: Robby Ruijtenbeek, Maria Helena Hilhorst, Arzu Umar, Johannes Albert Foekens, Johannes Wilhelmus Maria Martens
  • Patent number: 9040048
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: May 26, 2015
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 9029513
    Abstract: A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: May 12, 2015
    Assignees: Toagosei Co. Ltd., Keio University
    Inventors: Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
  • Publication number: 20150125449
    Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 7, 2015
    Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter Von Kreudenstein
  • Publication number: 20150125868
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
  • Patent number: 9023996
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Synimmune GmbH
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
  • Patent number: 9017683
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 28, 2015
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • Patent number: 8993728
    Abstract: The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: March 31, 2015
    Assignees: Medical and Biological Laboratories Co., Ltd., Oncomics Co., Ltd.
    Inventors: Ken-ichiro Ono, Takashi Takahashi
  • Publication number: 20150079082
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Gregory Alan LAZAR, Arthur Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 8980267
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 17, 2015
    Assignee: ImmunGene Inc
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
  • Patent number: 8980262
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2015
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20150073129
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 12, 2015
    Inventors: Frank Herting, Sabine Hoves, Carola Ries, Katharina Wartha
  • Publication number: 20150072918
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: March 18, 2014
    Publication date: March 12, 2015
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Patent number: 8974786
    Abstract: Provided herein are humanized forms of murine RP215 monoclonal antibodies and methods of using the same. These humanized RP215 monoclonal antibodies were characterized in terms of their respective affinity and specificity to the corresponding tumor-associated antigen, CA215, and shown to be comparable to those of murine RP215.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 10, 2015
    Assignee: Vancouver Biotech Ltd.
    Inventor: Gregory Lee
  • Patent number: 8975382
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: March 10, 2015
    Assignee: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Patent number: 8969530
    Abstract: A purified monoclonal antibody, or an. antigen-binding portion thereof, which specifically binds to human clathrin heavy chain (CHC) is disclosed. The antibody, or antigen-binding portion, thereof, exhibits at least one, two, three, four, five, six, seven, or all eight of the following properties: (a) specifically binds to pancreatic adenocarcinoma cells; (b) binding to the cell surface and cytosol of cancer cells and tumor blood vessels; (c) internalized by CHC-expressing cells; (d) inhibiting tumor growth, invasion ability, migration, and angiogenesis; (e) inducing apoptosis in cancer cells and human umbilical vein endothelial cells; (f) inhibiting tumor growth and tumor blood vessels in pancreatic cancer in vivo; (g) suppressing epidermal growth factor, transferrin, and VEGF internalizations by cancer cells; and (h) suppressing hypoxia-inducible factor-1? expression and vascular endothelial growth factor secretion.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: March 3, 2015
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, Kuo-Hua Tung
  • Publication number: 20150056635
    Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 26, 2015
    Inventors: Weimin Qi, David Tacha
  • Patent number: 8961971
    Abstract: This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 24, 2015
    Assignees: Development Center for Biotechnology, DCB-USA LLC
    Inventors: Yu-Shen Hsu, Show-Shan Sheu, Ming-I Chang, Ming-Chuan Chang, Ta-Tung Yuan
  • Patent number: 8962806
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: February 24, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Publication number: 20150037340
    Abstract: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: November 5, 2012
    Publication date: February 5, 2015
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
  • Patent number: 8946388
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: February 3, 2015
    Assignee: Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8946387
    Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, more particularly the extracellular domain of Fc?RIIB with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA, and block the Fc binding site of Fc?RIIB. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: February 3, 2015
    Assignee: MacroGenics, Inc.
    Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
  • Patent number: 8945554
    Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: February 3, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 8940298
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Publication number: 20150024956
    Abstract: Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers.
    Type: Application
    Filed: November 19, 2012
    Publication date: January 22, 2015
    Inventors: Arsen Batagov, Anna Ivshina, Vladimir Kuznetsov
  • Patent number: 8937158
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: January 20, 2015
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Patent number: 8921525
    Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: December 30, 2014
    Assignee: Tohoku University
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
  • Publication number: 20140371429
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.
    Type: Application
    Filed: April 10, 2014
    Publication date: December 18, 2014
    Applicant: GENENTECH, INC.
    Inventors: Matthew Marrichi, Dorothea E. Reilly
  • Publication number: 20140370022
    Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.
    Type: Application
    Filed: February 20, 2014
    Publication date: December 18, 2014
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Seok-Hyung KIM, Do-Hyun NAM, Hyun-Kyu PARK, Kyeung Min JOO, Nam Kyung LEE
  • Patent number: 8912311
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: December 16, 2014
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 8901278
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 2, 2014
    Assignee: Amgen Research (Munich) GmbH
    Inventors: Doris Rau, Susanne Mangold, Peter Kufer, Tobias Raum
  • Patent number: 8900816
    Abstract: Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 2, 2014
    Assignee: Duke University
    Inventors: Robert J. Schmittling, Gary E. Archer, John H. Sampson, Darell D. Bigner
  • Patent number: 8901281
    Abstract: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Paul Ponath, Patricia Rao, Michael Rosenzweig, L. Mary Smith, Jose F. Ponte
  • Patent number: 8900582
    Abstract: A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Kwang-ho Cheong, Seung-hyun Lee
  • Patent number: 8900819
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: December 2, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Rohit Mehra
  • Patent number: 8895007
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: November 25, 2014
    Assignee: Affitech Research AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Patent number: 8883974
    Abstract: T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: November 11, 2014
    Assignee: Immunovative Therapies, Ltd.
    Inventor: Michael Har-Noy
  • Patent number: 8877899
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: November 4, 2014
    Assignee: Morphosys AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Publication number: 20140322130
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 30, 2014
    Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
  • Patent number: 8871908
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: October 28, 2014
    Assignee: Rinat Neuroscience Corp.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Publication number: 20140315746
    Abstract: Compositions and methods for the diagnosis, treatment and prevention of prostate cancer, well as for treatment selection.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 23, 2014
    Inventors: William B. Isaacs, Kathryn A. Cooney
  • Patent number: 8865873
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 21, 2014
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • Patent number: 8865875
    Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 21, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jie Liu, David King
  • Publication number: 20140308287
    Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to ErbB3 and aspects relating to such constructs.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 16, 2014
    Applicant: Sea Lane Biotechnologies, LLC
    Inventors: Ramesh R. Bhatt, Pamela K. Foreman, Lawrence C. Horowitz, Michael Horowitz, Medini Gore, Phil Kobel
  • Patent number: 8858942
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 14, 2014
    Assignee: MedImmune Limited
    Inventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang